Kestra Advisory Services, LLC Jounce Therapeutics, Inc. Transaction History

Kestra Advisory Services, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 31, 2023	SELL	$0.64 - $1.99 $6,560 - $20,397	-10,250 Reduced 28.2%	26,100 $28,000
Q3 2022 Nov 01, 2022	BUY	$2.73 - $4.92 $27,573 - $49,692	10,100 Added 38.48%	36,350 $85 Million
Q2 2022 Aug 12, 2022	BUY	$2.8 - $7.67 $2,240 - $6,136	800 Added 3.14%	26,250 $80,000
Q2 2021 Jul 28, 2021	SELL	$6.58 - $10.66 $6 - $10	-1 Reduced -0.0%	25,450 $173,000
Q1 2021 May 10, 2021	SELL	$6.73 - $13.87 $68,975 - $142,153	-10,249 Reduced 28.71%	25,451 $261,000
Q4 2020 Jan 20, 2021	BUY	$6.37 - $10.33 $65,292 - $105,882	10,250 Added 40.28%	35,700 $238 Million
Q3 2020 Nov 12, 2020	BUY	$4.58 - $10.95 $116,561 - $278,677	25,450 New	25,450 $208 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Kestra Advisory Services, LLC with notifications on news.